News / Events

Emerald Health Therapeutics Promotes Paul R. Dillman, Jr. to Executive Vice President of Global Sales and Marketing

VICTORIA, British Columbia, Oct. 11, 2018 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (TSXV:EMH; OTCQX:EMHTF) (“Emerald”) today announced the promotion of Paul R. Dillman, Jr. to Executive Vice President of Global Sales and Marketing. Mr. Dillman previously served as Vice President of Sales and Marketing, and will now be responsible for leading international marketing, sales, and customer services for Emerald as the company prepares to participate in the new legal cannabis landscape.  

“Paul has been instrumental in preparing the Emerald brand for adult-use legalization in Canada,” said Chris Wagner, Chief Executive Officer of Emerald. “With our branding, marketing and sales strategy, Emerald is poised to be a premiere provider of cannabis for medical and adult-use consumers. Paul’s marketing expertise has been invaluable to our team over the past few months, and we look forward to positioning Emerald to be a leader in Canada as well as the global cannabis industry.”

Mr. Dillman has three decades of experience in global marketing, sales, and general management and prior to Emerald, held senior leadership positions at The Coca-Cola Company, AB InBev, Philip Morris, and Kraft Foods. Mr. Dillman earned a bachelor of science from West Point (United States Military Academy) and a master of science in systems management from the University of Southern California.

The Company has granted 50,000 stock options to Mr. Dillman to purchase up to an aggregate of 50,000 common shares of the Company at an exercise price of $4.60 per Option Share, vesting over a period of three years and exercisable for five years from the date of grant.

About Emerald Health Therapeutics, Inc.

Emerald Health Therapeutics, Inc. (TSXV: EMH; OTCQX: EMHTF; Frankfurt: TBD) is a Licensed Producer under Canada’s Access to Cannabis for Medical Purposes Regulations and produces and sells dried cannabis and cannabis oil for medical purposes. Emerald owns 50% of Pure Sunfarms, which is converting a licensed existing 1.1 million square foot greenhouse in Delta, BC, and is in commercial production. It owns Agro-Biotech, a Québec-based licensed cannabis grower with a 75,000 square foot indoor facility. Emerald has also entered into hemp chaff purchase agreements in 2018 and subsequent years. Emerald’s team is highly experienced in life sciences, product development, large-scale agri-business, and marketing, and is focused on developing value-added cannabis-based products with potential wellness and medical benefits. Emerald is part of the Emerald Health group, which is broadly focused on developing pharmaceutical, botanical, and nutraceutical products that may provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.

Please visit www.emeraldhealth.ca for more information or contact:
Rob Hill, Chief Financial Officer
(800) 757 3536 Ext. #5

Ray Lagace, Investor Relations Manager
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements. Such statements include legalization of nonmedicinal cannabis; Emerald becoming a premiere provider of cannabis; and expansion of facilities.

We cannot guarantee that any forward-looking statement will materialize, and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties related to, among other things, failure to obtain regulatory approvals; failure to obtain necessary financing; results of production and sale activities; results of scientific research; regulatory changes; changes in prices and costs of inputs; demand for labor; demand for products; as well as the risk factors described in the Company’s annual information form and other regulatory filings. The forward-looking statements contained in this press release represent our expectations as of the date hereof. Forward-looking statements are presented for the purpose of providing information about management's current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. The Company undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law.

EHT.jpg

Source: Emerald Health Therapeutics Inc.